Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ERENUMAB Cause Product use in unapproved indication? 192 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 192 reports of Product use in unapproved indication have been filed in association with ERENUMAB (AIMOVIG). This represents 16.2% of all adverse event reports for ERENUMAB.

192
Reports of Product use in unapproved indication with ERENUMAB
16.2%
of all ERENUMAB reports
131
Deaths
124
Hospitalizations

How Dangerous Is Product use in unapproved indication From ERENUMAB?

Of the 192 reports, 131 (68.2%) resulted in death, 124 (64.6%) required hospitalization, and 124 (64.6%) were considered life-threatening.

Is Product use in unapproved indication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ERENUMAB. However, 192 reports have been filed with the FAERS database.

What Other Side Effects Does ERENUMAB Cause?

Off label use (293) Migraine (285) Drug ineffective (280) Gastrooesophageal reflux disease (236) Drug intolerance (227) Vomiting (220) Pain (217) Abdominal pain upper (210) Blepharospasm (209) Hypoaesthesia (204)

What Other Drugs Cause Product use in unapproved indication?

DUPILUMAB (33,452) DICLOFENAC (12,197) METHOTREXATE (8,930) PREDNISONE (7,625) RITUXIMAB (7,519) MYCOPHENOLATE MOFETIL (5,910) ACETAMINOPHEN (5,819) CYCLOPHOSPHAMIDE (5,750) RISPERIDONE (5,551) TACROLIMUS (5,057)

Which ERENUMAB Alternatives Have Lower Product use in unapproved indication Risk?

ERENUMAB vs ERENUMAB-AOOE ERENUMAB vs ERENUMAB\ERENUMAB-AOOE ERENUMAB vs ERGOCALCIFEROL ERENUMAB vs ERGOCALCIFEROL\PHYTONADIONE\RETINOL\TOCOPHEROL ERENUMAB vs ERIBULIN

Related Pages

ERENUMAB Full Profile All Product use in unapproved indication Reports All Drugs Causing Product use in unapproved indication ERENUMAB Demographics